Goldman Sachs’s bluebird bio BLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-64,950
| Closed | -$317K | – | 6094 |
|
|
2025
Q1 | $317K | Buy |
64,950
+2,932
| +5% | +$17.6K | ﹤0.01% | 5425 |
|
|
2024
Q4 | $517K | Buy |
62,018
+21,758
| +54% | +$190K | ﹤0.01% | 5233 |
|
|
2024
Q3 | $418K | Buy |
40,260
+19,887
| +98% | +$331K | ﹤0.01% | 5149 |
|
|
2024
Q2 | $401K | Sell |
20,373
-13,668
| -40% | -$274K | ﹤0.01% | 4939 |
|
|
2024
Q1 | $871K | Sell |
34,041
-29,788
| -47% | -$764K | ﹤0.01% | 4433 |
|
|
2023
Q4 | $1.76M | Buy |
63,829
+25,790
| +68% | +$1.57M | ﹤0.01% | 4023 |
|
|
2023
Q3 | $2.31M | Sell |
38,039
-14,891
| -28% | -$1.05M | ﹤0.01% | 3657 |
|
|
2023
Q2 | $3.48M | Sell |
52,930
-27,458
| -34% | -$2.01M | ﹤0.01% | 3423 |
|
|
2023
Q1 | $5.11M | Sell |
80,388
-7,514
| -9% | -$858K | ﹤0.01% | 3037 |
|
|
2022
Q4 | $12.2M | Buy |
87,902
+13,049
| +17% | +$1.84M | ﹤0.01% | 2411 |
|
|
2022
Q3 | $9.48M | Sell |
74,853
-17,941
| -19% | -$2.03M | ﹤0.01% | 2558 |
|
|
2022
Q2 | $7.68M | Sell |
92,794
-11,897
| -11% | -$923K | ﹤0.01% | 2759 |
|
|
2022
Q1 | $10.2M | Buy |
104,691
+28,653
| +38% | +$3.78M | ﹤0.01% | 2681 |
|
|
2021
Q4 | $15.2M | Sell |
76,038
-40,035
| -34% | -$9.45M | ﹤0.01% | 2377 |
|
|
2021
Q3 | $28.7M | Sell |
116,073
-20,934
| -15% | -$5.98M | 0.01% | 1729 |
|
|
2021
Q2 | $56.8M | Buy |
137,007
+58,361
| +74% | +$23.1M | 0.01% | 1141 |
|
|
2021
Q1 | $30.7M | Sell |
78,646
-907
| -1% | -$447K | 0.01% | 1569 |
|
|
2020
Q4 | $44.6M | Buy |
79,553
+24,134
| +44% | +$15.3M | 0.01% | 1203 |
|
|
2020
Q3 | $38.7M | Sell |
55,419
-22,932
| -29% | -$17.9M | 0.01% | 1189 |
|
|
2020
Q2 | $62M | Buy |
78,351
+12,498
| +19% | +$9.42M | 0.02% | 807 |
|
|
2020
Q1 | $39.2M | Sell |
65,853
-2,196
| -3% | -$2.14M | 0.01% | 1033 |
|
|
2019
Q4 | $77.3M | Buy |
68,049
+27,727
| +69% | +$30.1M | 0.02% | 855 |
|
|
2019
Q3 | $48M | Sell |
40,322
-16,911
| -30% | -$25.8M | 0.01% | 1130 |
|
|
2019
Q2 | $94.3M | Buy |
57,233
+7,244
| +14% | +$12.5M | 0.03% | 720 |
|
|
2019
Q1 | $102M | Sell |
49,989
-4,020
| -7% | -$7.08M | 0.03% | 652 |
|
|
2018
Q4 | $69.4M | Buy |
54,009
+18,576
| +52% | +$28.5M | 0.02% | 839 |
|
|
2018
Q3 | $67M | Sell |
35,433
-28,559
| -45% | -$59M | 0.02% | 1021 |
|
|
2018
Q2 | $130M | Buy |
63,992
+15,055
| +31% | +$34.3M | 0.04% | 590 |
|
|
2018
Q1 | $108M | Buy |
48,937
+29,163
| +147% | +$74.2M | 0.03% | 725 |
|
|
2017
Q4 | $45.6M | Sell |
19,774
-1,771
| -8% | -$3.6M | 0.01% | 1354 |
|
|
2017
Q3 | $38.3M | Sell |
21,545
-15,967
| -43% | -$22.3M | 0.01% | 1469 |
|
|
2017
Q2 | $51M | Buy |
37,512
+10,125
| +37% | +$12.2M | 0.01% | 1218 |
|
|
2017
Q1 | $32.2M | Buy |
27,387
+6,913
| +34% | +$7.05M | 0.01% | 1538 |
|
|
2016
Q4 | $16.4M | Buy |
20,474
+6,242
| +44% | +$4.96M | ﹤0.01% | 2100 |
|
|
2016
Q3 | $12.5M | Buy |
14,232
+2,259
| +19% | +$1.64M | ﹤0.01% | 2272 |
|
|
2016
Q2 | $6.71M | Sell |
11,973
-19,398
| -62% | -$11M | ﹤0.01% | 2633 |
|
|
2016
Q1 | $17.3M | Buy |
31,371
+10,833
| +53% | +$6.65M | 0.01% | 1830 |
|
|
2015
Q4 | $17.1M | Sell |
20,538
-6,715
| -25% | -$6.71M | 0.01% | 1865 |
|
|
2015
Q3 | $30.2M | Sell |
27,253
-787
| -3% | -$1.44M | 0.01% | 1409 |
|
|
2015
Q2 | $61.2M | Buy |
28,040
+8,427
| +43% | +$17.2M | 0.02% | 973 |
|
|
2015
Q1 | $30.7M | Sell |
19,613
-8,831
| -31% | -$11.7M | 0.01% | 1455 |
|
|
2014
Q4 | $33.8M | Buy |
28,444
+8,791
| +45% | +$5.87M | 0.01% | 1421 |
|
|
2014
Q3 | $9.13M | Sell |
19,653
-4,823
| -20% | -$2.23M | ﹤0.01% | 2437 |
|
|
2014
Q2 | $12.2M | Buy |
+24,476
| New | +$7.85M | ﹤0.01% | 2213 |
|
|
2014
Q1 | – | Sell |
-2,791
| Closed | -$758K | – | 6764 |
|
|
2013
Q4 | $758K | Buy |
2,791
+538
| +24% | +$150K | ﹤0.01% | 4978 |
|
|
2013
Q3 | $787K | Buy |
+2,253
| New | +$837K | ﹤0.01% | 4789 |
|
Other funds holding BLUE
Goldman Sachs's BLUE Position: Q2 2025 in Review
Goldman Sachs sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 64,950 shares — an estimated $317K sold.
Goldman Sachs first reported a position in BLUE in Q3 2013 and held it in 46 quarters. The position peaked at $130M in Q2 2018. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.
- Goldman Sachs reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
- Goldman Sachs sold 64,950 bluebird bio shares in Q2 2025, an estimated $317K.
- Goldman Sachs first reported a position in bluebird bio in Q3 2013 and held it in 46 quarters.
- Goldman Sachs's bluebird bio position peaked at $130M in Q2 2018.
- 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.
Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.